Open an account

Pulmatrix

PULM · NASDAQ

$1.43+$0.01 (+0.70%)TodayMarket closed ·
Prev close $1.42

About PULM

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

Employees
2
Headquarters
Framingham, Massachusetts
Listed
Mar 21, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
pulmatrix.com

PULM key statistics

Market cap
5.22M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
33.13K
Volume
13.93K
Open price
$1.40
High today
$1.44
Low today
$1.39
52 Week high
$5.24
52 Week low
$1.16

Pulmatrix (PULM) at a glance

As of Oct 20, 2026, Pulmatrix (PULM) shares are priced at $1.43, giving the company a market cap of 5.22M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.39 and $1.44. The current price is 2.9% above the day's low and 0.7% below its high.

Volume so far is 13.93K shares, below the average of 33.13K shares a day.

Over the past year Pulmatrix has ranged from $1.16 to $5.24, and now sits 7% of the way up that range.

Pulmatrix met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY25 it reported -$0.42 per share against an estimate of $0.00.

PULM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 19.1% on average.

  1. Q3 FY22: reported -$1.45 per share against an estimate of -$1.54
  2. Q4 FY22: reported -$1.14 per share against an estimate of -$1.47
  3. Q1 FY23: reported -$1.22 per share against an estimate of $0.00
  4. Q4 FY23: reported -$0.57 per share against an estimate of -$1.06
  5. Q2 FY23: reported -$1.04 per share against an estimate of -$1.25
  6. Q3 FY23: reported -$1.03 per share against an estimate of -$1.07
  7. Q3 FY24: reported -$0.71 per share against an estimate of $0.00
  8. Q2 FY25: reported -$0.42 per share against an estimate of $0.00

PULM news

  • Press releasePRNewswire

    Are MGLD, NRIM, PULM Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    ACT NOW: The M&A Class Action Firm Is Investigating the Merger--LXP, LXFR, NRIM, and PULM

  • Press releasePRNewswire

    Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN

  • Press releasePRNewswire

    Pulmatrix Announces First Quarter 2026 Financial Results

  • Press releasePRNewswire

    Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

  • Press releaseBusiness Wire

    PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Pulmatrix

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.